1,3'-联吡咯烷 | 267241-99-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1,3'-联吡咯烷
• 中文别名: 1-(3-吡咯烷)吡咯烷
• 英文名称: 1-(pyrrolidin-3-yl)pyrrolidine
• 英文别名: 1,3'-Bipyrrolidine；1-pyrrolidin-3-ylpyrrolidine
• CAS: 267241-99-6
• 化学式: C₈H₁₆N₂
• mdl: MFCD06740353
• 分子量: 140.228
• InChiKey: HFZLSTDPRQSZCQ-UHFFFAOYSA-N

物化性质

• 沸点：
  215.5±8.0 °C(Predicted)
• 密度：
  1.014±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P261,P264,P270,P271,P280,P302+P352,P304+P340,P305+P351+P338,P310,P330,P332+P313,P362,P403+P233,P405,P501
• 危险品运输编号：
  2735
• 危险性描述：
  H302,H315,H318,H335

反应信息

• 作为反应物：
  描述：

  1,3'-联吡咯烷 在 palladium diacetate 、 caesium carbonate 、 三乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.5h， 生成 1-(5-((4-([1,3'-bipyrrolidin]-1'-yl)-5-chloropyrimidin-2-yl)amino)pyridin-3-yl)pyrrolidin-2-one
  参考文献：
  名称：

  INHIBITORS AND DEGRADERS OF PIP4K PROTEIN

  摘要：

  Provided are compounds and compositions which modulate the level or activity of PIP4K2C. Also provided are methods for treating diseases or conditions by modulating (e.g., reducing) the level or activity of a PIP4K2C, comprising administering the compounds and compositions.

  公开号：

  WO2024107746A1
• 作为产物：
  描述：

  Tert-butyl 3-pyrrolidin-1-ylpyrrolidine-1-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.0h， 生成 1,3'-联吡咯烷
  参考文献：
  名称：

  Benzimidazole- and indole-substituted 1,3′-bipyrrolidine benzamides as histamine H3 receptor antagonists

  摘要：

  Using a focused screen of biogenic amine compounds we identified a novel series of H3R antagonists. A preliminary SAR study led to reduction of MW while increasing binding affinity and potency. Optimization of the physical properties of the series led to (S)-6n, with improved brain to plasma exposure and efficacy in both water intake and novel object recognition models. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.122
• 作为试剂：
  描述：

  庚酸 、 alkaline earth salt of/the/ methylsulfuric acid 在 1,3'-联吡咯烷 、 溶剂黄146 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 121.3h， 生成 17α-ethynyl-7α-methyl-3-oxo-5(10)-estren-17-yl heptanoate
  参考文献：
  名称：

  7α-methylnorethindrone enanthate 10β-hydroperoxide: Isolation and characterization

  摘要：

  10 beta-Hydroperoxy-7 alpha-methylnorethindrone 17-heptanoate (II), a product of allylic autoxidation of 7 alpha-methylnorethindrone enanthate (I), has been isolated and characterized. The synthesis of the hydroperoxide (II) from the 3-ethylene ketal of 7 alpha-methylnorethynodrel (III) was achieved. Esterification of alcohol (III), subsequent deketalization, and photochemical oxygenation resulted in the hydroperoxide (II). Reduction of the hydroperoxide (II) to the 10 beta-alcohol (VI) and acetylation of (II) to the 10 beta-acetoxyperoxide (VII) are described. A single subcutaneous injection of the compounds (II), (VI), and (VII) to rats failed to produce long term inhibition of fertility in contrast to the parent compound (I) which is at least five times more effective than norethindrone enanthate as measured by suppression of vaginal cornification and estrous cycles.

  DOI：

  10.1016/0039-128x(83)90138-1

文献信息

• [EN] COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS<br/>[FR] COMPOSÉS POUR INHIBER LA PROLIFÉRATION CELLULAIRE DANS LES CANCERS INDUITS PAR L'EGFR
  申请人：ARIAD PHARMA INC

  公开号：WO2013169401A1

  公开（公告）日：2013-11-14

  The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula (I), wherein the variables are as defined herein.

  这项发明涉及化合物、药物组合物和治疗EGFR驱动的Formula (I)癌症患者的方法，其中变量如本文所定义。
• Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones
  申请人：Armour R. Duncan

  公开号：US20080085884A1

  公开（公告）日：2008-04-10

  The present invention provides for MCHR1 antagonist compounds of formula (I) and the pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein the substituents are as defined herein, and the pharmaceutically acceptable salts, solvates and prodrugs thereof, which are useful in treating diseases or conditions wherein antagonism of the MCHR1 receptor is beneficial.

  本发明提供了式（I）的MCHR1拮抗剂化合物及其药用盐、溶剂合物和前药，其中取代基如本文所定义，并且其药用盐、溶剂合物和前药，可用于治疗对MCHR1受体拮抗有益的疾病或症状。
• SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS
  申请人：Dahmann Georg

  公开号：US20130023502A1

  公开（公告）日：2013-01-24

  The invention relates to new substituted pyridinyl-pyrimidines of formula 1 wherein ring A is a five-membered saturated or unsaturated carbocyclic ring which optionally comprises one, two or three heteroatoms each independently from each other selected from the group N, S and O, wherein R 1 , R 2 , R 4 , R 3 , R 5 and R 6 are defined as in claim 1 and wherein ring A is further optionally substituted by one or two further substituents and the pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates and solvates of the aforementioned compounds.

  该发明涉及公式1中的新取代吡啶基嘧啶化合物， 其中环A是一个含有五个成员的饱和或不饱和碳环，该环可选地包含一个、两个或三个异原子，每个异原子独立地选自N、S和O组成， 其中R1、R2、R4、R3、R5和R6如权利要求书中所定义，并且环A进一步可选地被一个或两个进一步取代基取代，以及上述化合物的药用盐、二对映体、对映体、消旋体、水合物和溶剂化合物。
• [EN] BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS<br/>[FR] COMPOSITIONS DE BENZOPIPÉRAZINE EN TANT QU'INHIBITEURS DE BROMODOMAINES BET
  申请人：BAIR KENNETH W

  公开号：WO2015074081A1

  公开（公告）日：2015-05-21

  The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein X, Y, Z, R1, R2, R4 and R7 are defined herein.

  本发明涉及用于治疗癌症、炎症性疾病、糖尿病和肥胖的溴和末端（BET）溴结构域抑制剂，具有公式（I）：其中X、Y、Z、R1、R2、R4和R7的定义如下。
• Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
  申请人：SUGEN, Inc.

  公开号：US20040186160A1

  公开（公告）日：2004-09-23

  The present invention is directed to a class indolinone compounds, hexahydro-cyclohepta-pyrrole oxindoles, which are useful as protein kinase inhibitors.

  本发明涉及一类吲哚酮化合物，即六氢-环庚-吡咯酮氧吲哚，其作为蛋白激酶抑制剂具有用途。